Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Acquisitions & Divestments (2016 - 2025)

United Therapeutics' Change in Acquisitions & Divestments history spans 17 years, with the latest figure at $485.5 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 1.57% year-over-year to $485.5 million; the TTM value through Dec 2025 reached $1.6 billion, up 3.05%, while the annual FY2025 figure was $1.6 billion, 3.05% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $485.5 million at United Therapeutics, up from $182.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $2.1 billion in Q4 2023 and bottomed at -$892.0 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $382.8 million (2022), against an average of $383.8 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 725.0% in 2021 before it tumbled 156.63% in 2022.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at -$892.0 million in 2021, then skyrocketed by 43.21% to -$506.6 million in 2022, then surged by 521.89% to $2.1 billion in 2023, then crashed by 77.64% to $478.0 million in 2024, then rose by 1.57% to $485.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Change in Acquisitions & Divestments are $485.5 million (Q4 2025), $182.5 million (Q3 2025), and $915.9 million (Q2 2025).